Washington State

Office of the Attorney General

Attorney General

Bob Ferguson

Sep 1 2021
OLYMPIA — Attorney General Bob Ferguson announced today he will appeal Purdue Pharma’s flawed bankruptcy plan. Ferguson asserts that the plan is inadequate, and that a bankruptcy court doesn’t have the authority to prevent attorneys general from enforcing state law, including the decision to pursue the company’s owners, the Sackler family, for their illegal conduct.
Aug 26 2021
BELLINGHAM — Attorney General Bob Ferguson today announced that, as a result of his antitrust consent decree, Bellingham Anesthesia Associates (BAA) must end its illegal dominance of the local health care market and pay $110,000 in costs and fees. BAA used unlawful non-compete clauses and exclusive contracts with area medical providers to take about 90 percent of the market share for physician-administered anesthesia services in Whatcom and Skagit counties. This legally enforceable agreement requires BAA to cease illegally requiring physicians to sign three-year non-compete contracts.
Aug 9 2021
Attorney General Bob Ferguson issued the following statement after two key legal victories on Friday in Washington’s case against opioid distributors McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Drug Corp.
Jul 21 2021
OLYMPIA — Attorney General Bob Ferguson today announced that he formally rejected a proposed settlement with opioid distributors McKesson, Cardinal Health and Amerisource Bergen, and Johnson & Johnson. The Attorney General’s Office has been litigating against these companies for years. Trial against McKesson, Cardinal Health and Amerisource Bergen begins in King County Superior Court on September 7. Ferguson’s trial against Johnson & Johnson is scheduled to begin in King County Superior Court in January 2022.
Jul 19 2021
Attorney General Bob Ferguson led eight other attorneys general in filing a formal objection today [LINK] asking the judge to reject Purdue Pharma’s proposed bankruptcy plan, which includes a lifetime legal shield for the company’s owners, the Sackler family. The states argue that a bankruptcy court doesn’t have the authority to prevent attorneys general from enforcing state law, including the decision to pursue the Sacklers for their illegal conduct.
Jun 17 2021
In the wake of today’s U.S. Supreme Court ruling upholding the Affordable Care Act (ACA), Attorney General Bob Ferguson offered the following statement, and a fact sheet detailing the ACA’s impact on Washington state. Washington state was part of the coalition defending the ACA, because the Trump Administration refused.
Feb 4 2021
SEATTLE — As a result of an investigation launched by Attorney General Bob Ferguson, McKinsey, a multinational consulting firm that worked with Purdue Pharma, will pay $13,465,833 to the Washington State Attorney General’s Office. Ferguson is directing the entire amount to be invested in treatment, prevention and other efforts to address the opioid epidemic in Washington.
Nov 18 2020
SEATTLE — A King County Superior Court judge today found AmerisourceBergen Drug Corp., one of the largest prescription opioid distributors in the world, in contempt of court for failing to turn over important documents and attempting to shield key witnesses from testifying. AmerisourceBergen is one of the three companies Attorney General Bob Ferguson sued in March 2019 for unlawfully contributing to Washington state’s opioid epidemic.
Nov 18 2020
OLYMPIA — Attorney General Bob Ferguson issued the following statement today after a federal judge in northern California ruled that the Trump Administration’s reinterpretation of a long-standing provision of the Medicaid Act that allows voluntary payroll deductions — such as union dues and health care premiums — from payments to in-home caregivers is invalid.
Sep 24 2020
Attorney General Bob Ferguson today announced that Bard, a medical device manufacturer and formerly one of the biggest manufacturers of transvaginal mesh devices, will pay $2.38 million to Washington for misrepresentations and failure to include serious risks in the instructions and marketing materials for surgical mesh devices.

Pages